Can a 49-year-old patient with multiple myeloma who underwent a bone marrow transplant on [date] receive vaccines now?

Vaccination After Bone Marrow Transplant in Multiple Myeloma

Yes, your 49-year-old multiple myeloma patient can and should receive vaccines now, but the specific timing and type of vaccines depend on how many months have passed since her transplant and whether she has graft-versus-host disease (GVHD) or is on immunosuppression.

Timing Framework for Vaccination Post-Transplant

The vaccination schedule is structured around time intervals from transplant, with different vaccines becoming appropriate at different timepoints:

Inactivated Vaccines (Safe and Recommended)

Starting at 3-4 months post-transplant:

• Influenza vaccine can begin as early as 4 months after autologous transplant, though some guidelines recommend waiting until 4-6 months 1. Given the high infection risk early post-transplant, earlier vaccination (around 3 months) is supported by data showing comparable immune responses 1.

Starting at 6-12 months post-transplant: Most inactivated vaccines should begin in this window 1:

• Pneumococcal conjugate vaccine (PCV13): 3 doses at 6-12 months, followed by PPSV23 after completing the series (≥12 months total)
• DTaP (diphtheria/tetanus/pertussis): 3 doses starting at 6-12 months
• Hepatitis A: 2 doses starting at 6-12 months
• Hepatitis B: 3 doses starting at 6-12 months
• Meningococcal conjugate vaccine: 1-2 doses at 6-12 months
• Inactivated polio vaccine: 3 doses starting at 6-12 months
• HPV vaccine: 3 doses starting at 6-12 months (particularly important for your 49-year-old patient, as HPV vaccination is recommended up to age 45) 2, 1

Recombinant zoster vaccine (Shingrix):

• Can start as early as 50-70 days after autologous transplant 1
• May be considered after allogeneic transplant but timing is less established

Live Vaccines (Restricted - Require Special Conditions)

Not before 24 months (2 years) post-transplant and only if ALL of the following criteria are met 2, 1:

• No active GVHD
• No systemic immunosuppression for at least 8-12 months (some sources specify no immunosuppression for a full year before varicella)
• No IVIG for 8-11 months prior to vaccination

Live vaccines that may be considered at ≥24 months if criteria met:

• MMR (measles/mumps/rubella): 1-2 doses for seronegative patients
• Varicella vaccine: Two doses 1 month apart for varicella-seronegative patients without history of primary varicella

Critical Considerations for Your Patient

If She's on Maintenance Therapy

Good news: Research demonstrates that vaccination is both safe and effective in multiple myeloma patients on lenalidomide maintenance therapy 3. A study of 122 patients showed:

• 75% were on lenalidomide maintenance at time of vaccination
• Response rates: 76% to pertussis, 70% to diphtheria, 60% to tetanus, 71% to H. influenzae, 58% to pneumococcal
• No difference in response rates between those on maintenance versus those not on maintenance
• No vaccine-related adverse effects 3

Similarly, live-attenuated vaccines (MMR and herpes zoster) were shown to be safe and well-tolerated in 137 multiple myeloma patients on maintenance lenalidomide or bortezomib post-transplant, with no rash attributed to vaccine strains 4.

Type of Transplant Matters

Autologous transplant (more common in multiple myeloma):

• Generally allows earlier vaccination
• Less severe immune reconstitution issues
• Can start some vaccines at 3-4 months

Allogeneic transplant:

• Requires more conservative approach
• Higher risk of GVHD complicating vaccination timing
• Patients are essentially considered "never vaccinated" and need complete revaccination 1

Practical Algorithm for Your Patient

Step 1: Determine time since transplant

• If <3 months: Hold all vaccines except in special circumstances
• If 3-6 months: Consider influenza vaccine
• If 6-12 months: Begin comprehensive inactivated vaccine series
• If ≥24 months: Evaluate for live vaccine eligibility

Step 2: Assess contraindications to live vaccines

• Active GVHD? → No live vaccines
• On immunosuppression? → No live vaccines
• Received IVIG in last 8-11 months? → No live vaccines
• All clear? → Can consider MMR/varicella if seronegative

Step 3: Prioritize vaccines based on risk

• Highest priority: Influenza (annual), pneumococcal series, recombinant zoster
• High priority: DTaP, hepatitis B, meningococcal
• Important: HPV (given her age of 49, still within recommended range), hepatitis A, polio

Step 4: Consider maintenance therapy

• Lenalidomide or bortezomib maintenance does NOT preclude vaccination 4, 3
• Proceed with inactivated vaccines as scheduled
• B-cell depleting therapies (like rituximab, daratumumab, or anti-BCMA therapies) may reduce response but vaccination is still recommended 5, 6

Common Pitfalls to Avoid

1. Don't delay inactivated vaccines unnecessarily: While guidelines recommend 6-12 months for most vaccines, evidence supports starting influenza and pneumococcal vaccines earlier (3-4 months) given high infection risk 1

2. Don't give live vaccines too early: The 24-month rule for live vaccines is firm and requires absence of GVHD and immunosuppression 2, 1

3. Don't skip vaccines because patient is on maintenance therapy: Evidence clearly shows safety and efficacy of vaccination during lenalidomide or bortezomib maintenance 4, 3

4. Don't forget HPV vaccine: At age 49, your patient is still within the recommended age range (up to 45 years, with consideration beyond), and post-transplant patients have heightened risk of HPV-related cancers 2, 1

5. Don't assume one dose is enough: Most vaccines require multiple doses (typically 3) given at 4-week intervals due to poor immune response post-transplant 1

The Bottom Line

Begin inactivated vaccines now if your patient is ≥6 months post-transplant, regardless of maintenance therapy status. Start with influenza (if in season), pneumococcal conjugate vaccine, and recombinant zoster vaccine as the highest priorities. Live vaccines must wait until at least 24 months post-transplant and only if she has no GVHD, no immunosuppression for the past year, and no recent IVIG. The most recent ASCO 2024 guidelines 2 and European Myeloma Network 2021 consensus 1 provide the framework, with research confirming safety even during maintenance therapy 4, 3.